ro glp-1 program SERENA WILLIAMS JOINS AS CELEBRITY AMBASSADOR Ro Weight Loss Commercial: Revolutionizing

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study

The current literature and expert consensus suggest that while these medications can be transformative for clinical populations (diabetics/obese patients), they offer no magic pill for a fit athlete beyond possible weight reduction and that weight loss can come at the expense of performance-critical factors like decreased muscle mass and inadequate fuelling

E.MontanyaE.BrettJ

Finally, GLP-1s affect both insulin and glucagon release

China produces an estimated 70% of the global peptide raw material supply

SELECT was the first trial to underline the efficacy of the treatment in patients with obesity independent of the concomitant presence of T2D